Melda Bahap, Kutay Demirkan, Pinar Bakir Ekinci, Sehnaz Alp, Serife Gul Oz

Liposomal Amphotericin B Induced Acute Reactions

Three formulations of amphotericin B are available: liposomal, lipid complex and conventional. The liposomal amphotericin B is more preferred agent than other formulations because of its tolerability, safety and potent antifungal activity. However, the liposomal amphotericin B can cause infusion-related reactions. In this case report, we aimed to report a patient who developed infusion-related reactions during the treatment with the liposomal amphotericin B but eventually tolerated the prolonged infusion. In this case report, we present a patient who developed an infusion-related reaction during The liposomal amphotericin B treatment. A 26-year-old male patient with acute promyelocytic leukemia was hospitalized for the third course of chemotherapy. Due to the invasive fungal infection history in previous hospitalizations, the liposomal amphotericin B 400 mg (IV, 5 mg/kg) once daily was initiated as secondary antifungal prophylaxis. Swelling in infusion site and chest pain were reported within 10 minutes of the liposomal amphotericin B administration, and the infusion rate was slowed down to 400 mg/6 hours from 400 mg/2 hours. All these reactions disappeared with prolonged infusion time. The patient received a total of 7 liposomal amphotericin B doses subsequently without any reaction during the chemotherapy cycle. In our experience, the liposomal amphotericin B-induced infusion-related reactions can be resolved by prolonging the infusion time.

PDF

___

[1] Collazos J, Martinez E, Mayo J, et al. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management. Clin Infect Dis 2001; 33(7): E75-82.
[2] Hagihara M, Yamagishi Y, Hirai J, et al. Drug-induced hypersensitivity syndrome by liposomal amphotericin-B: a case report. BMC Res Notes 2015; 8: 510.
[3] Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20(4): 755-61.
[4] Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340(10): 764-71.
[5] Tollemar J, Ringden O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf 1995; 13(4): 207-18.
[6] Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/ III clinical trial. J Antimicrob Chemother 1991; 28 Suppl B: 83-91.
[7] Arning M, Heer-Sonderhoff AH, Wehmeier A, et al. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995; 14(1): 41-3.
[8] Cutaia M, Bullard SR, Rudio K et al. Characteristics of amphotericin B-induced endothelial cell injury. J Lab Clin Med 1993; 121(2): 244-56.
[9] Sullivan GW, Carper HT, Mandell GL. Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro. Antimicrob Agents Chemother 1992; 36(2): 408-16.
[10] McDonnell TJ, Chang SW, Westcott JY, et al. Role of oxidants, eicosanoids, and neutrophils in amphotericin B lung injury in rats. J Appl Physiol 1988; 65(5): 2195-206.
[11] Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 1998; 18(5): 1053-61.
[12] Gigliotti F, Shenep JL, Lott L, et al. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J Infect Dis 1987; 156(5): 784-9.
[13] Food and Drug Administration. AmBisome® (amphotericin B) liposome for injection. https://www.accessdata.fda. gov/drugsatfda_docs/label/2008/050740s016lbl.pdf (accessed June 2019).
[14] Schoffski P, Freund M, Wunder R, et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 1998; 317(7155): 379-84.